Program

Under the guidance of Professor Eva Segelov, Meeting Convenor, and the Annual Scientific Meeting Executive Organising Committee, the 2018 Program has been developed and will once again provide a forum for mutual exchange of knowledge to improve the treatment of patients with gastro-intestinal cancer.

The format of the program is such that each day starts with a Keynote Breakfast session featuring Key Opinion Leaders. Throughout the three days of the program are Plenary sessions, AGITG Trials sessions, the New Concepts Symposium, Poster Review and Best of Posters/Fast Forward sessions and specialist workshops including the Joint Consumer-Study Coordinator sessions, Trainees Workshop and Multi-Disciplinary Workshops. At the conclusion of the first day of the program is the Welcome Function and the Annual Reception and Dinner are held on the second evening.

Wednesday 31 October 2018

Brisbane Convention and Exhibition Centre

0700 – 2000

Registration Open

Boulevard Foyer

0800 – 0900

Keynote Breakfast Session
Chair: Professor Eva Segelov
“Taking sides in metastatic colorectal cancer: predictive and prognostic factors in selecting therapy”
– Professor Sabine Tejpar

P9, P10, P11

0800 – 0900

Combined Surgical-Radiation Oncology Breakfast
Co-Chairs: Associate Professor Andrew Kneebone and Dr Iain Thomson
“State of the Art Therapies for Rectal Cancer”

“Optimal surgical management of rectal cancer”
– Professor Brendan Moran

“Optimal radiotherapy techniques in rectal cancer”
– Professor Daniel Chang

P7

0900 – 1030

Opening Plenary
Co-Chairs: Professor Tim Price and Dr Iain Thomson
“Feast or famine: too much or not enough in colorectal cancer”

“Past, present and future in primary and secondary detection of CRC”
– Professor Graeme Young

“Rectal cancer: are we under using or over using surgery?”
Professor Brendan Moran

“Rectal cancer: are we under using or over using radiation therapy?”
Professor Daniel Chang

“Rectal cancer: are we under using or over using chemotherapy?”
Professor Eva Segelov

Amgen

Plenary: B1, B2, B3

1030 – 1100

Morning Tea

Boulevard Room / Exhibition

1100 – 1300

AGITG Early Colorectal Cancer Trials
Co-Chairs: Dr Amitesh Roy and Professor Bridget Robinson

A La CaRT: Australasian Laparoscopic Cancer of the Rectum Trial. A phase III prospective randomised trial comparing laparoscopic-assisted resection versus open resection for rectal cancer
Associate Professor Andrew Stevenson

SPAR: A randomized, placebo-controlled phase II trial of Simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer
Associate Professor Michael Jameson

DYNAMIC-Rectal: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Locally Advanced Rectal Cancer: A Multicentre Randomised Study
Presented with DYNAMIC-III: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Randomised Study
Associate Professor Jeanne Tie

ASCOLT: Aspirin for Dukes C and High-Risk Dukes B Colorectal Cancers. An International, Multi-centre, Double Blind, Randomised Placebo Controlled Phase III Trial
Presented with ASCOLT Translational
Dr Mark Jeffery

RENO: Prospective Study of ‘Watch and Wait’ Strategy in Patients with Rectal Cancer who have Developed a Clinical Complete Response with concurrent chemo-radiotherapy: RENO (Rectal Cancer No Operation)
Professor Chris Karapetis

AGITG Early Colorectal Cancer Trials Portfolio – How does this fit in to the International Context?
Professor Brendan Moran

Plenary: B1, B2, B3

1300 – 1400

Lunch

Boulevard Room / Exhibition

1400 – 1600

AGITG Advanced Colorectal Cancer Trials
Co-Chairs: Dr Michael Jameson and Professor Chris Karapetis

MODULATE: Modulation of the tumour microenvironment using either vascular disrupting agents or STAT3 inhibition in order to synergise with PD1 inhibition in microsatellite stable, refractory colorectal cancer
Associate Professor Niall Tebbutt

LIBERATE: A study evaluating liquid biopsies to profile metastatic colorectal cancer
Associate Professor Niall Tebbutt

MONARCC: A randomised phase 2 study of panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer
Dr Matthew Burge

InterAACT: An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin plus 5-fluorouracil versus Carboplatin plus Weekly Paclitaxel in Patients with Inoperable Locally Recurrent or Metastatic Disease;
Presented with InterAACT2: International, multicentre, open label, randomised phase III trial of chemotherapy alone v chemotherapy (i.e., Cisplatin-5FU or Carboplatin-Paclitaxel) plus anti-PD-1 inhibitor
Dr Amitesh Roy

AGITG Advanced Colorectal Cancer Trials Portfolio – How does this fit in to the International Context?
Professor Sabine Tejpar

“Incorporating Comorbidity in Clinical Trials: damned if you do, damned if you don’t”
Professor Diana Sarfati
This talk will give an overview of the importance of comorbidity on the outcomes for people with cancer, the benefits and challenges of incorporating comorbidity assessments into clinical trials, and the dangers that await if we do not carefully consider comorbidity in trial design.

Plenary: B1, B2, B3

1400 – 1600

Radiation Oncology Workshop
Co-Chairs: Dr Hien Le and Dr Andrew Oar

“SBRT for Pancreas Cancer”
Invited Faculty: Professor Daniel Cheng
National Expert Panel: Dr Hien Le, Dr Andrew Oar and Dr David Pryor
A practical discussion on selection and technique for delivering SBRT for pancreas cancer including discussion of proposed AGITG pancreas SBRT guidelines.

P7

1600 – 1645

Afternoon Tea

Boulevard Room / Exhibition

1645 – 1815

CRC Multidisciplinary Workshop
Co-Chairs: Dr Christopher Jackson and Dr Rachel Wong

International Expert Panel: Professor Brendan Moran, Professor Daniel Chang, Professor Sabine Tejpar
National Expert Panel: Dr Craig Underhill, Professor Andrew Kneebone, Professor Graeme Young

MDM showcasing clinical scenarios in controversial areas of diagnosis and management, such as total neoadjuvant therapy for colon and rectal cancers. Featuring an expert panel with audience interaction.

Plenary: B1, B2, B3

1815 – 1845

Trainees Workshop
Co-Chairs: Dr Christopher Jackson and Professor Eva Segelov

A career in oncology is highly rewarding and increasingly popular. An increasing number of trainees and a competitive job market means that now, more than ever, trainees need to be thoughtful and strategic about planning their training with an eye to the job market. This workshop presents a unique opportunity to meet with senior and successful medical, surgical and radiation oncologists who have followed varied paths to their current position. This workshop will explore the many different opportunities available to trainees, and how to navigate training, research, service, teaching, fellowships, and how to flourish as a clinician, researcher, leader, teacher, or all four in Australia and New Zealand.

P7

1815 – 2000

Welcome Reception

Boulevard Room / Exhibition

Thursday 1 November 2018

Brisbane Convention and Exhibition Centre

0800 – 0900

Keynote Breakfast Session
Chair: Dr Mustafa Khasraw

“What light through yonder window breaks; the dawn of routine molecular pathology”
Professor Aldo Scarpa

Professor Scarpa will discuss molecular and morphologic aspects of modern pancreas cancer pathology, and the opportunities and limitations of genomically driven cancer care, functioning of tumour boards, serial tumour biopsies and the implications of tumour heterogeneity.

P9, P10, P11

0900 – 1100

Translational Science Symposium
Co-Chairs: Dr Jayesh Desai and Dr Sharon Pattison

“Lost in Translation? – Evolving insights into Molecular and Immunological Targets in GI Cancers”

This years’ Translational Science Symposium brings together a group of leading Australian translational researchers with some of our invited faculty, to focus on reaping the benefits clinically from the major advances in understanding molecular and immunological targets in GI cancers. The session will comprise a mix of longer thematic presentations, short talks and a panel discussion; and has particular relevance given the challenges we clearly are having to face in bench-bedside translation in GI cancers compared to other cancer types, especially in relation to immunotherapy.

“What can the clinician learn from recent advances in molecular classification of CRC?”
Professor Sabine Tejpar

“Immunological approaches to targeting ‘cold’ tumours”
Dr Michele Teng

“Molecular and Immunological targets in G/O cancers”
Professor Jae-Ho Cheong

Amgen

Plenary: B1, B2, B3

1100 – 1130

Morning Tea

Boulevard Room / Exhibition

1130 – 1315

Translational Science Symposium continues
Co-Chairs: Dr Jayesh Desai and Dr Sharon Pattison

“Best of Australian Translational Science in GI Cancers”
Professor Robert Ramsay
Associate Professor Oliver Sieber
Dr Vicki Whitehall
Associate Professor Michael Samuels
Dr Tracy Putoczki
Professor Alex Boussioutas
Dr Danielle Ferraro

Plenary: B1, B2, B3

1130 – 1315

Radiation Oncology Contouring Workshop “SBRT for Liver Cancer”
Chair: Associate Professor Andrew Kneebone

Invited Faculty: Professor Daniel Chang
National Expert Panel: Dr Dominique Lee, Dr Julie Chu & Dr David Pryor

Prof Daniel Cheng is a world expert on Liver SBRT and we will have a practical workshop discussing cases and reviewing the art of liver SBRT including selection, imaging, contouring, planning, image verification and follow up.

P7

1315 – 1415

Lunch and Poster Review

Boulevard Room / Exhibition

1415 – 1600

New Concepts Symposium
Co-Chairs: Professor Tim Price and Dr Katrin Sjoquist

The New Concepts Symposium sponsored by Specialised Therapeutics Australia is designed as a novel way to reach out to a wider spectrum of the group. This session provides an opportunity for delegates to present embryonic new concepts for feedback and discussion with the audience as well as comments from international guests in terms of perspective, international interest and relevance.
A good idea can be tested and a perception gained on whether to take the concept forward to a more formal review by the Upper or Lower GI Working Party. The identification of other AGITG members who may wish to assist in progressing the concept as an AGITG supported protocol is also possible.
The winner of the Best New Concept Award will receive a $3,500 prize and a framed certificate. The runner up will receive a $1,500 prize and framed certificate. The Awards are presented at the Annual Scientific Meeting Dinner and details of the Award recipients are published on the AGITG website and in the Annual Report.

“A phase 2 study of regorafenib combined with Aspirin in RAS mutated advanced Colorectal Cancer”
Dr Rahul Ladwa
Invited Faculty: Prof Sabine Tejpar

“A pilot feasibility and discovery study of neoadjuvant FOLFIRINOX followed by immunotherapy for resectable adenocarcinoma of the pancreas”
Dr Lorraine Chantrill
Invited Faculty: Dr Daniel Renouf

“Phase 2 trial of Metformin in Oesophageal Adenocarcinoma“
Dr Monica Tang
Invited Faculty: Prof Jae-Ho Cheong

“Using the CancerAid® mobile app to collect toxicity and quality of life data to improve the efficiency of trial data collection”
Dr Wee Loon Ong
Invited Faculty: Prof Diana Sarfati

Plenary: B1, B2, B3

1600 – 1630

Afternoon Tea

Boulevard Room / Exhibition

1630 – 1800

Best of Posters / Fast Forward
Co-Chairs: Dr Craig Underhill and Dr Mark Jeffery

The AGITG Annual Scientific Meeting accepts abstracts for posters for selection by the Executive Organising Committee. Posters are displayed in the exhibition area. Four posters are chosen for presentation in the Best of the Best Session. Each presenter has seven minutes to present with three minutes for questions.

Four posters are also chosen for Fast Forward presentation. Each presenter has three minutes to present with two minutes for questions.

The AGITG recognises excellence in the Posters and Fast Forward Sessions at each annual meeting. The winning presenter in the Posters Session receives a $3,500 prize and framed certificate. The winning presenter in the Fast Forward session receives $1,500 and a framed certificate. The Awards are presented at the Annual Scientific Meeting Dinner and details of the Award recipients are published on the AGITG website and in the Annual Report.

Plenary: B1, B2, B3

1630 – 1800

Joint Consumer/Study Coordinator Forum
Co-Chairs: Ms Jan Mumford and Ms Anne Smith

In this year’s Joint Consumer/ Study Coordinators session, the presenters have updates on current GI cancer research. These include immunology, where are we for GI cancers, and the challenges and learnings from rare cancers. Additionally, is the opportunities with tele trials and an update on health economics. Building on last year’s talk of a Study Coordinators day, we have a behind the scenes snapshot from a Trials Manager. Finally, financial toxicity is another stress for patients, out of pocket expenses, may influence treatment decisions.

Hot Issues: Liquid Biopsies
Associate Professor Jeanne Tie

Rare Cancers
Professor David Goldstein

Tele Trials
Ms Chris Aiken and Ms Kerry Lenton

Financial Toxicity
Ms Jan Mumford and Ms Simone Leyden

A day in the life of a Trials Manager
Mr Martijn Oostendorp

Health Economics
Dr Hannah Carter

P7

1900 – 2000

AGITG 20th Annual Meeting Reception

Boulevard Room / Exhibition

2000 – 2300

AGITG 20th Annual Meeting Dinner

P9, P10, P11

Friday 2 November 2018

Brisbane Convention and Exhibition Centre

0900 – 1030

Keynote Breakfast Session
Co-Chairs: Dr Ben Lawrence and Dr Jenny Shannon

“Science Meets Reality”
Real world patients we see every day are not reflective of those recruited to randomised studies, so trial results may not apply to the patients we see every day. Also, there is variation in practice around the world which may be in part due to differences in cancer risk factors, genetic predisposition, histological sub-types, as well as referral and reimbursement patterns. What can we learn from real-world variations in care? Are outcome and practice differences due to genuine differences in cancers and risk factors, or is it doctor-driven? What can we learn from routinely collected datasets, and how should we interpret or ignore clinical trial evidence in a real world context?

“RCT’s and other Fake News: statistical fallacies and the new world order of big data”
Professor Diana Sarfati
This presentation will examine some of the differences between clinical and statistical significance, the limits and benefits of routine and administrative data sets, commonly held statistical mistruths, and the value of non-randomised trial data when determining causality.

“East v West: are all OG cancers the same?”
Professor Jae-Ho Cheong
Clinical practice in the management of oesophagogastric cancer varies between East and West. This lecture will review the epidemiological, genomic, and clinical differences in OG cancer, asking what we can learn from around the world, challenging our own paradigms and practices.

“Microbiome & Mapping: are we what we eat?”
Professor Sabine Tejpar
Humans are host to a vast and diverse microbial climate that has until recently been overlooked. Increasingly, investigators are beginning to identify microbes, or groups of microbiota, that are important in pathogenesis of disease, as well as susceptibility to immunotherapy. This talk explores the relationship between the microbiome and GI cancer risk, treatment and outcome, and the role of food on the microbiome.

P9, P10, P11

1030 – 1100

Morning Tea

Boulevard Room / Exhibition

1100 – 1230

AGITG UGI, HPB, GIST & NET Cancer Research
Co-Chairs: Dr Julie Chu and Professor Mark Smithers

INTEGRATE II: A Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer
Associate Professor Nick Pavlakis

DOCTOR: A Randomised Phase II Trial of pre-operative cisplatin, 5 fluorouracil and docetaxel, +/-Radiotherapy, based on poor early response to standard chemotherapy for resectable adenocarcinoma of the oesophagus and/or gastro oesophageal junction
Presented with DOCTOR Translational: Improving oesophageal adenocarcinoma outcomes through understanding genomics and treatment toxicity
Professor Andrew Barbour

GAP: Phase II study of Gemcitabine and nab‐Paclitaxel for Resectable Pancreas Cancer
Professor David Goldstein

ACTICCA-1: Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gall bladder carcinoma
Dr Jenny Shannon

CONTROL NETS: Capecitabine ON Temozolomide Radionuclide therapy Octreotate Lutetium-177 NeuroEndocrine Tumours Study
Associate Professor Nick Pavlakis

NABNEC: A Randomised Phase II Study Of nab‐paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas
Dr Mustafa Khasraw

TOPGEAR: A randomised II/III trial of preoperative chemoradiotherapy versus preoperative chemotherapy for resectable gastric cancer
Professor Trevor Leong

AGITG UGI, HPB, GIST & NET Cancer Research Portfolio – How does this fit in to the International Context?
Surgical trials – Professor Jae-Ho Cheong
Local therapy trials – Dr Daniel Renouf

Plenary: B1, B2, B3

1230 – 1330

Lunch

Boulevard Room / Exhibition

1330 – 1530

International Expert Panel: Pancreas Cancer
Chair: Professor Eva Segelov

After many decades of negative studies or minor incremental improvement in standards for pancreas cancer, there has been a sudden acceleration in positive clinical trial data in the neo-adjuvant, adjuvant, and metastatic setting. In this session, our domestic and international experts will address new clinical trial data, treatment strategies, patient selection, and explore the potential for integration of genomics and immunotherapy into research trials and clinical practice.

“Adjuvant therapy: is there a new standard of care?”
Dr Lorraine Chantrill

“Total neo-adjuvant therapy: ready for prime time?”
Professor Andrew Barbour: Surgical perspective
Professor Daniel Chang: Radiation perspective
Professor David Goldstein: Medical Oncology perspective

“Integrating genomic profiling into pancreas cancer management”
Professor Aldo Scarpa

“Is there a future for immunotherapy in pancreas cancer?”
Dr Dan Renouf

Plenary: B1, B2, B3

1530

Close of ASM 2018

1545

Buses depart to the Airport